⚠ Evidence warning: Clinical trials or other evidence do not support the claim that andrographis protects the human liver against acetaminophen, alcohol, fatty liver disease, chronic hepatitis and aflatoxin liver cancer; the evidence is animal and cell work, and no human liver trial was found. This page keeps it as a report of what people, websites or other media say.

Andrographis for Liver Protection

Liver Protection — scientific infographic poster

Andrographis has been used as a hepatoprotective remedy in Ayurveda, traditional Chinese medicine, and traditional Thai medicine for at least a thousand years. Its Sanskrit name Bhunimba ("earth neem") explicitly identifies it as the terrestrial counterpart of the bitter bile-supporting neem tree. The Chinese name Chuan Xin Lian (literally "through-heart lotus") points to its use for liver-heat, jaundice, and dampness syndromes. The modern molecular story justifies the traditional use: andrographolide is a cholagogue (stimulates bile production and flow), a Nrf2 activator (induces phase-II detoxification enzymes including glutathione-S-transferase, glutathione peroxidase, NAD(P)H quinone oxidoreductase 1 (NQO1), and heme oxygenase-1), and, in mouse studies, an inducer of the CYP1A1 and CYP1A2 enzymes (it switches them on rather than blocking them). Animal trials document protection against acetaminophen, ethanol, carbon tetrachloride, aflatoxin, and galactosamine hepatotoxicity. This deep-dive walks through the molecular biology, the comparison with the more famous silymarin (milk thistle) model, the clinical applications in fatty liver, hepatitis, and drug-induced liver injury, and the doses described for liver-support uses.


Table of Contents

  1. Traditional Use as a Hepatoprotective Herb
  2. Cholagogue Activity (Bile Flow Stimulation)
  3. Nrf2 / Keap1 / ARE Antioxidant Response
  4. Phase-II Detoxification Enzyme Induction
  5. CYP P450 Induction and Carcinogen Bioactivation
  6. Acetaminophen (Paracetamol) Hepatotoxicity Protection
  7. Alcohol-Induced Liver Injury
  8. Non-Alcoholic Fatty Liver Disease (NAFLD)
  9. Aflatoxin and Hepatocarcinogenesis
  10. Comparison with Silymarin (Milk Thistle)
  11. Clinical Applications and Dosing
  12. Cautions and Drug Interactions
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Traditional Use as a Hepatoprotective Herb

Andrographis paniculata appears in the Charaka Samhita (~1st-2nd century CE) and the Sushruta Samhita as a remedy for kamala (jaundice), raktapitta (bleeding disorders associated with liver dysfunction), and chronic fevers with liver involvement. The classical Ayurvedic preparation Kalmegh ghana (a concentrated leaf extract) was prescribed for hepatitis, sluggish digestion, and ascites long before modern hepatology distinguished viral hepatitis from autoimmune hepatitis from drug-induced liver injury. Andrographis remains a constituent of several traditional polyherbal hepatoprotective formulations.

In traditional Chinese medicine, Chuan Xin Lian is classified as a cold, bitter herb that clears heat, dries dampness, and resolves toxin — the classical syndrome pattern that corresponds to modern conditions including acute viral hepatitis, cholangitis, and cholestatic jaundice. It is also used as a primary herb in traditional Chinese medicine formulations for the alarmingly named "damp-heat in the gallbladder" pattern, which translationally corresponds to cholecystitis and cholelithiasis with chronic biliary inflammation.

In traditional Thai medicine, Andrographis (called Fa Thalai Chon) is a Pillar Herb of the National Drug List and is dispensed by the Ministry of Public Health for hepatitis adjunct therapy, along with its better-known upper respiratory tract infection (URTI) applications.

Back to Table of Contents

Cholagogue Activity (Bile Flow Stimulation)

A cholagogue is any agent that increases bile flow from the gallbladder into the duodenum (distinct from a choleretic, which increases bile production by hepatocytes — many cholagogues are also choleretics). Improved bile flow matters clinically for several reasons:

Andrographis is one of a relatively small number of herbs with documented choleretic and cholagogue activity in controlled animal studies. Andrographolide and the related congeners stimulate hepatocyte bile-acid synthesis and increase the rate of bile-salt secretion into the canaliculus. The effect is modest compared with pharmaceutical cholagogues (ursodeoxycholic acid, dehydrocholic acid) but is meaningful in the context of sluggish digestion, gallbladder hypokinesia, and the lingering biliary effects of post-cholecystectomy syndrome.

Andrographis is used for symptoms attributed to poor bile flow — chronic fat malabsorption, pale stools after fatty meals, post-cholecystectomy diarrhea, gallbladder hypomotility on imaging — as part of a broader approach that may also include ox bile, taurine, and smaller amounts of dietary fat.

Back to Table of Contents

Nrf2 / Keap1 / ARE Antioxidant Response

The Nrf2 / Keap1 system is the master regulator of cellular antioxidant and phase-II detoxification gene expression. Under baseline conditions, the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) is held in the cytoplasm bound to its repressor Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for proteasomal degradation. When the cell experiences oxidative stress, electrophilic challenge, or exposure to specific Nrf2-activating molecules, key reactive cysteine residues on Keap1 are modified, the Keap1-Nrf2 complex dissociates, and Nrf2 translocates to the nucleus.

In the nucleus, Nrf2 heterodimerizes with small Maf proteins and binds the antioxidant response element (ARE) sequence in the promoter regions of over 200 downstream target genes. The downstream targets include:

Andrographolide is a documented Nrf2 activator via covalent modification of Keap1 cysteine residues (analogous to the action of sulforaphane from broccoli sprouts, dimethyl fumarate from the multiple sclerosis drug class, and curcumin). Multiple animal models confirm that andrographolide administration upregulates expression of glutathione-S-transferase, NQO1, HO-1, and the glutathione synthesis machinery in liver tissue, with measurable increases in hepatic glutathione concentration after a few weeks of dosing.

The protective effect of Nrf2 induction is broad. It buffers against drug-induced and chemical-induced oxidative damage, accelerates clearance of phase-I-activated reactive intermediates, and reduces the rate at which environmental and metabolic toxins damage hepatic DNA. This is the same mechanism behind the cancer-chemoprevention activity of cruciferous vegetables and is part of the broader case for "induce phase-II, inhibit phase-I" detoxification strategies in chronic illness.

Back to Table of Contents

Phase-II Detoxification Enzyme Induction

The conventional hepatic detoxification model divides metabolism into Phase-I (CYP P450-mediated oxidation, reduction, hydrolysis — creates a reactive intermediate from a foreign molecule) and Phase-II (conjugation of the intermediate to glutathione, glucuronide, sulfate, glycine, taurine, methyl — makes it water-soluble for renal or biliary excretion). The reactive Phase-I intermediates are themselves often more toxic than the parent molecule, and the Phase-II enzymes are what neutralize and clear them.

A pattern of relative Phase-I overactivity with Phase-II underactivity is a recurring problem in chronic illness, in genetic detoxification polymorphisms (slow-acetylator NAT2 variants, slow GSTT1/GSTM1 null genotypes), and in the burden of cumulative environmental exposure. The result is accumulation of reactive intermediates that drive chronic oxidative damage and contribute to chemical-induced cancers, autoimmune triggering, and the broad category of multiple chemical sensitivity.

Nrf2 induction is the principal upstream lever for shifting the Phase-I / Phase-II balance toward better conjugation and clearance. Andrographolide is one of the most accessible and well-tolerated Nrf2 activators in the herbal pharmacopeia, alongside sulforaphane (broccoli sprouts), curcumin (turmeric), silymarin (milk thistle), and the carotenoids astaxanthin and beta-carotene.

Back to Table of Contents

CYP P450 Induction and Carcinogen Bioactivation

The other half of the detoxification story is Phase-I CYP P450 modulation. The CYP family of approximately 50 hepatic enzymes performs the initial oxidative modification of most foreign molecules — pharmaceuticals, dietary xenobiotics, and many environmental toxins. Three CYP isoforms in particular bioactivate pre-carcinogens into their reactive carcinogenic forms:

Laboratory and animal studies show andrographolide switching on (inducing) the bioactivating enzymes, not blocking them. In mouse liver cells, andrographolide raised CYP1A1 and CYP1A2 in a dose-dependent way, and together with standard CYP1A-inducing chemicals (including the smoke-type hydrocarbon benz[a]anthracene and dioxin) it induced CYP1A1 more strongly than either did alone; the authors describe this as the first report of andrographolide's power to induce CYP1A1 (Jaruchotikamol 2007). In mice fed an Andrographis extract (50 or 100 mg/kg a day for 14 days), total liver cytochrome P450 and cytochrome P450 reductase rose, along with the phase-II enzymes glutathione-S-transferase and DT-diaphorase (Singh 2001). What this means for medicines broken down by CYP1A2 (caffeine, theophylline, clozapine) in people has not been tested.

The phase-II side of the picture is what the mouse work supports: Singh and colleagues concluded that the enzyme changes "indicate the chemopreventive potential of Andrographis paniculata against chemotoxicity including carcinogenicity." Long-term andrographolide administration has also been described as reducing polycyclic-aromatic-hydrocarbon-induced gastric tumors and chemically induced mammary tumors in animal models.

Back to Table of Contents

Acetaminophen (Paracetamol) Hepatotoxicity Protection

Acetaminophen (US) / paracetamol (UK, much of the world) is among the most-used analgesics globally and the leading cause of acute liver failure in the US and several European countries. The hepatotoxic mechanism is well-mapped: acetaminophen is normally glucuronidated and sulfated for excretion, with a small fraction routed through cytochrome P450 2E1 to the highly reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI). NAPQI is normally rapidly neutralized by hepatic glutathione conjugation. When the acetaminophen dose overwhelms the glucuronidation and sulfation pathways (whether by single overdose or by repeated supratherapeutic dosing in chronic-pain patients), more substrate is shunted through cytochrome P450 2E1 to NAPQI, and when hepatic glutathione is depleted, NAPQI binds covalently to hepatocyte proteins causing centrilobular necrosis.

The standard rescue therapy is N-acetylcysteine (NAC, a glutathione precursor) given orally or intravenously within the first hours after overdose. Andrographolide attacks the same problem upstream:

Multiple animal trials in mice and rats document that prophylactic andrographolide administration substantially reduces the liver-enzyme elevation and histologic necrosis from a hepatotoxic acetaminophen dose. Andrographolide is not a substitute for N-acetylcysteine in acute overdose management. Its proposed use as a protective measure for people taking acetaminophen long term above the usual dose for pain (chronic osteoarthritis, cancer pain, post-surgical pain) rests on these animal results.

Back to Table of Contents

Alcohol-Induced Liver Injury

Alcoholic liver disease (steatosis, alcoholic hepatitis, fibrosis, cirrhosis) is driven by a combination of acetaldehyde toxicity (the proximate ethanol metabolite produced by alcohol dehydrogenase and cytochrome P450 2E1), oxidative stress from chronic cytochrome P450 2E1 induction, gut-derived endotoxin (lipopolysaccharide) reaching the liver via the portal vein and activating Kupffer cell tumor necrosis factor-alpha and interleukin-6 (IL-6) production, and direct toxic effects on hepatocyte mitochondria.

Andrographolide's hepatoprotective effects in alcohol-induced liver injury are well-documented in animal studies and act through several complementary mechanisms:

Andrographis has been proposed as an adjunct to alcohol cessation, diet, and conventional management for people in early recovery from alcohol use disorder with elevated liver enzymes, on the strength of these animal studies. It does not make continued drinking safe. The fundamental treatment is alcohol cessation; established alcoholic steatosis takes months to resolve after it.

Back to Table of Contents

Non-Alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (now formally renamed metabolic dysfunction-associated steatotic liver disease (MASLD)) affects an estimated 25-30% of adults in developed countries and is now the leading cause of chronic liver disease worldwide. The pathophysiology centers on insulin resistance driving hepatic de novo lipogenesis, mitochondrial dysfunction, oxidative stress, and a chronic low-grade inflammatory state that can progress to non-alcoholic steatohepatitis (NASH, now renamed metabolic dysfunction-associated steatohepatitis, MASH) and ultimately to fibrosis, cirrhosis, and hepatocellular carcinoma.

Animal-model evidence for Andrographis in non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease is encouraging; no human fatty-liver trial of Andrographis was found in PubMed:

For non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease management, Andrographis is again described as an adjunct to the foundational interventions (caloric restriction, weight loss of 7-10% of body weight, exercise, low-carbohydrate or Mediterranean dietary pattern, treatment of insulin resistance), not a replacement for them. The regimen described for this use is a 3-6 month course of Andrographis 400-600 mg standardized extract twice daily, alongside the foundational interventions, in people with elevated alanine aminotransferase (ALT)/aspartate aminotransferase (AST) and biopsy-confirmed or imaging-confirmed steatosis; it has not been tested in a human trial.

See our Fatty Liver Disease page for the broader management context.

Back to Table of Contents

Aflatoxin and Hepatocarcinogenesis

Aflatoxin B1, produced by Aspergillus flavus mold contamination of stored grain, peanuts, tree nuts, and corn, is one of the most potent natural carcinogens known. Chronic dietary aflatoxin exposure is a major contributor to hepatocellular carcinoma (HCC) incidence in much of sub-Saharan Africa and Southeast Asia, often acting synergistically with chronic hepatitis B virus infection. The molecular mechanism is well-mapped: cytochrome P450 3A4 (and to a lesser extent CYP1A2) oxidizes aflatoxin B1 to the highly reactive aflatoxin-B1-8,9-epoxide, which binds covalently to guanine residues in DNA and produces the characteristic AGG-to-AGT codon-249 mutation in the p53 tumor suppressor gene seen in aflatoxin-driven HCC.

It has been proposed that long-term andrographolide could reduce aflatoxin DNA adduct formation, preneoplastic foci formation in liver, and ultimate HCC incidence; no animal or human study testing this against liver cancer was found in PubMed. The proposed mechanism combined CYP1A2 inhibition (reducing aflatoxin bioactivation), glutathione-S-transferase induction (accelerating conjugation and excretion of whatever epoxide is formed), and AMP-activated protein kinase activation (promoting hepatocyte apoptosis of cells that have sustained DNA damage rather than allowing them to progress to malignant transformation). The first part does not match the laboratory findings: in mouse studies andrographolide induces CYP1A2 rather than inhibiting it (see above). The closest direct study is in farm animals: in pigs fed aflatoxin B1, which suppressed liver genes for detoxification and antioxidant defence, kalmegh (Andrographis) in the feed gave a broad rise in genes of key liver pathways, more than milk thistle did, and the authors conclude such herbs could counteract aflatoxin's effects on liver gene activity (Nalpadan 2026); the study measured gene activity, not cancer.

For people in high-aflatoxin-exposure regions (subsistence farmers, populations dependent on home-stored corn and peanuts), Andrographis has been put forward as a candidate chemopreventive addition to the more important measures of grain-storage modernization, hepatitis B vaccination, and dietary diversification; it has not been tested for this purpose.

Back to Table of Contents

Comparison with Silymarin (Milk Thistle)

The most-studied hepatoprotective botanical in Western herbal medicine is silymarin from milk thistle (Silybum marianum), a flavonolignan complex with similar Nrf2-activating and membrane-stabilizing properties to andrographolide. The two herbs are mechanistically complementary rather than redundant:

The two are often used together in practice. A combination described for hepatic support in chronic liver disease is silymarin 200-400 mg twice daily plus Andrographis 400 mg standardized extract twice daily, taken with food. The combination is described as well tolerated and mechanistically complementary, and no interactions between the two herbs have been reported.

Back to Table of Contents

Clinical Applications and Dosing

Uses and doses described for Andrographis in liver support (none has been tested in a human liver trial; see the Cautions for the human liver-enzyme finding):

All of these uses sit alongside the foundational hepatic-health measures: lower alcohol intake, good macronutrient quality, enough dietary protein for glutathione synthesis (cysteine is the rate-limiting amino acid), a healthy body weight, less exposure to known environmental hepatotoxins (mold-contaminated foods, industrial solvent exposure, unnecessary medications), and treatment of insulin resistance where present.

Back to Table of Contents

Cautions and Drug Interactions

Back to Table of Contents

Key Research Papers

  1. Trivedi NP, Rawal UM (2001). Hepatoprotective and antioxidant property of Andrographis paniculata (Nees) in BHC induced liver damage in mice. Indian Journal of Experimental Biology. — PubMed PMID: 11349524
  2. Visen PK, Shukla B, Patnaik GK, Dhawan BN (1993). Andrographolide protects rat hepatocytes against paracetamol-induced damage. Journal of Ethnopharmacology. — PubMed PMID: 8133653
  3. Singh RP, Banerjee S, Rao AR (2001). Modulatory influence of Andrographis paniculata on mouse hepatic and extrahepatic carcinogen metabolizing enzymes and antioxidant status. Phytotherapy Research. — PubMed PMID: 11507728
  4. Trivedi N, Rawal UM, Patel BP (2007). Hepatoprotective effect of andrographolide against hexachlorocyclohexane-induced oxidative injury. Integrative Cancer Therapies. — PubMed PMID: 17761640
  5. Pan CW, Yang SX, Pan ZZ, et al. (2017). Andrographolide ameliorates d-galactosamine/lipopolysaccharide-induced acute liver injury by activating Nrf2 signaling pathway. Oncotarget. — PubMed PMID: 28465482
  6. Chua LS (2014). Review on liver inflammation and antiinflammatory activity of Andrographis paniculata for hepatoprotection. Phytotherapy Research. — PubMed PMID: 25043965
  7. Handa SS, Sharma A (1990). Hepatoprotective activity of andrographolide from Andrographis paniculata against carbontetrachloride. Indian Journal of Medical Research. — PubMed PMID: 2228074
  8. Pan Y, Abd-Rashid BA, Ismail Z, et al. (2011). In vitro modulatory effects of Andrographis paniculata, Centella asiatica and Orthosiphon stamineus on cytochrome P450 2C19 (CYP2C19). Journal of Ethnopharmacology. — PubMed PMID: 21093571
  9. Bardi DA, Halabi MF, Hassandarvish P, et al. (2014). Andrographis paniculata leaf extract prevents thioacetamide-induced liver cirrhosis in rats. PLOS ONE. — PubMed
  10. Nagalekshmi R, Menon A, Chandrasekharan DK, Nair CK (2011). Hepatoprotective activity of Andrographis paniculata and Swertia chirayita. Food and Chemical Toxicology. — PubMed PMID: 21983487
  11. Jaruchotikamol A, Jarukamjorn K, Sirisangtrakul W, Sakuma T, Kawasaki Y, Nemoto N (2007). Strong synergistic induction of CYP1A1 expression by andrographolide plus typical CYP1A inducers in mouse hepatocytes. Toxicology and Applied Pharmacology. — PubMed PMID: 17825862
  12. Kaewdech A, Nawalerspanya S, Assawasuwannakit S, Chamroonkul N, Jandee S, Sripongpun P (2022). The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: a cross sectional study. Scientific Reports. — PubMed PMID: 36309577
  13. Suwankesawong W, Saokaew S, Permsuwan U, Chaiyakunapruk N (2014). Characterization of hypersensitivity reactions reported among Andrographis paniculata users in Thailand using Health Product Vigilance Center (HPVC) database. BMC Complementary and Alternative Medicine. — PubMed PMID: 25539642
  14. Nalpadan AA, Reyer H, Oster M, et al. (2026). Transcriptional insights into aflatoxin B1 induced hepatotoxicity and comparative effects of medicinal herbs in pigs. BMC Veterinary Research. — PubMed PMID: 41535828

PubMed Topic Searches

  1. PubMed: Andrographolide hepatoprotection
  2. PubMed: Andrographolide Nrf2 detoxification
  3. PubMed: Andrographis cholagogue
  4. PubMed: Andrographolide NAFLD
  5. PubMed: Andrographolide CYP P450

Back to Table of Contents

Connections

Back to Table of Contents